4basebio annual shares outstanding
2022
2023
2024
2025
4basebio Shares Outstanding History (4BB)
4basebio reported 15.5M shares outstanding at the end of fiscal 2025.
View full 4basebio company overview4basebio annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 15.5M | 13,000 | +0.08% |
| 2024 | 2024-12-31 | 15.5M | 3.2M | +25.59% |
| 2023 | 2023-12-31 | 12.3M | 2,000 | +0.02% |
| 2022 | 2022-12-31 | 12.3M | — | — |
4basebio quarterly shares outstanding
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 15.5M | 13,000 | +0.08% |
| Q2 2025 | 2025-06-30 | 15.5M | — | — |
| Q4 2024 | 2024-12-31 | 15.5M | — | — |
4basebio shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, 4basebio's shares outstanding moved from 12.3M to 15.5M, a change of 3.2M. The latest reported quarter, Q4 2025, shows 15.5M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
reported period-end shares
TickerStat displays period-end common shares from official filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4basebio source filings ↗Community posts
4basebio expands synthetic-DNA manufacturing for personalised mRNA medicines
4basebio announced an expansion of its DNA offering on 7 September 2026. Manufacturing changes The company has added suite capacity and enhanced process controls and quality systems across its Cambridge high-quality and current-GMP operatio ...